Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

Authors: Dean Follmann, Meagan P. O’Brien, Jonathan Fintzi, Michael P. Fay, David Montefiori, Allyson Mateja, Gary A. Herman, Andrea T. Hooper, Kenneth C. Turner, Kuo- Chen Chan, Eduardo Forleo-Neto, Flonza Isa, Lindsey R. Baden, Hana M. El Sahly, Holly Janes, Nicole Doria-Rose, Jacqueline Miller, Honghong Zhou, Weiping Dang, David Benkeser, Youyi Fong, Peter B. Gilbert, Mary Marovich, Myron S. Cohen

Source: Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)

Subject Terms: Science

File Description: electronic resource

Relation: https://doaj.org/toc/2041-1723

Access URL: https://doaj.org/article/f53522c4468546fb9a6f21698f892bd1

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Authors: Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, Wenjun Zheng, Scott Rasmussen, Danielle Armas, Masaru Oshita, Cynthia Brinson, Steven Folkerth, Lori Faria, Ingeborg Heirman, Neena Sarkar, Bret J. Musser, Shikha Bansal, Meagan P. O'Brien, Kenneth C. Turner, Samit Ganguly, Adnan Mahmood, Ajla Dupljak, Andrea T. Hooper, Jennifer D. Hamilton, Yunji Kim, Bari Kowal, Yuhwen Soo, Gregory P. Geba, Leah Lipsich, Ned Braunstein, George D. Yancopoulos, David M. Weinreich, Gary A. Herman

Source: International Journal of Infectious Diseases, Vol 122, Iss , Pp 585-592 (2022)

Subject Terms: COVID-19, SARS-CoV-2, Monoclonal antibody, Casirivimab, Imdevimab, Infectious and parasitic diseases, RC109-216

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1201971222003800; https://doaj.org/toc/1201-9712

Access URL: https://doaj.org/article/2e38e7074cf04400bb5312a6c93e1302

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies

Authors: Andrea T. Hooper, Selin Somersan-Karakaya, Shane E. McCarthy, Eleftherios Mylonakis, Shazia Ali, Jingning Mei, Rafia Bhore, Adnan Mahmood, Gregory P. Geba, Paula Dakin, David M. Weinreich, George D. Yancopoulos, Gary A. Herman, Jennifer D. Hamilton

Source: mBio, Vol 13, Iss 6 (2022)

Subject Terms: COVID-19, anti-SARS-CoV-2 serostatus, hospitalized, monoclonal antibodies, casirivimab and imdevimab, neutralizing antibodies, Microbiology, QR1-502

File Description: electronic resource

Relation: https://doaj.org/toc/2150-7511

Access URL: https://doaj.org/article/f95c3e647c9648b4b2d08445f92cd2c8

Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study

Authors: Jing Xiao, Paula Dakin, Gregory P Geba, Edward Cox, Rafia Bhore, Jennifer D Hamilton, Shazia Ali, Yogesh Patel, Thomas D Norton, Mazhar Thakur, Samit Ganguly, Jesse Chao, Alpana Waldron, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo-Watkins, Andrea T Hooper, Danise Subramaniam, Joseph A Bocchini, Bari Kowal, A. Thomas DiCioccio, Ned Braunstein, Gary A Herman

Source: BMJ Open, Vol 14, Iss 10 (2024)

Subject Terms: Medicine

File Description: electronic resource

Relation: https://bmjopen.bmj.com/content/14/10/e087431.full; https://doaj.org/toc/2044-6055

Access URL: https://doaj.org/article/b7231e34caf546898029db8ba1527a60

A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects.

Authors: Daniel M. Bloomfield, Rajesh Krishna, David Hreniuk, Lisa Hickey, Kalyan Ghosh, Arthur J. Bergman, Jutta Miller, Maria J. Gutierrez, Randall Stoltz, Keith M. Gottesdiener, Gary A. Herman, John A. Wagner

Source: Journal of Clinical Pharmacology; Aug2009, Vol. 49 Issue 8, p937-946, 10p

Subject Terms: MOXIFLOXACIN, PLACEBOS, CLINICAL pharmacology, ELECTROCARDIOGRAPHY, QUINOLONE antibacterial agents

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

Authors: Markolf Hanefeld¹, Gary A. Herman², Mei Wu², Carolyn Mickel², Matilde Sanchez², Peter P. Stein²

Source: Current Medical Research & Opinion. Jun2007, Vol. 23 Issue 6, p1329-1339. 11p.

Subject Terms: *HYPOGLYCEMIA treatment, *CD26 antigen, *PLACEBOS, *DRUG efficacy, *GLUCOSE

Human Pharmacokinetics and Interconversion of Enantiomers of MK-0767, a Dual PPARα/γ Agonist.

Authors: Ronda RKR Rippley, Kerri KXY Yan, Natalie NDM Matthews, Howard HEG Greenberg, Gary GAH Herman, John JAW Wagner

Source: Journal of Clinical Pharmacology; Mar2007, Vol. 47 Issue 3, p323-333, 11p

Subject Terms: ENANTIOMERS, TYPE 2 diabetes, PHARMACOKINETICS, PEROXISOMES

Multiple-Dose Administration of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Alter the Single-Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects.

Authors: Goutam GCM Mistry, Arthur AJB Bergman, Wen-Lin WL Luo, Caroline CC Cilissen, Wouter WH Haazen, Michael MJD Davies, Keith KMG Gottesdiener, John JAW Wagner, Gary GAH Herman

Source: Journal of Clinical Pharmacology; Feb2007, Vol. 47 Issue 2, p159-164, 6p

Subject Terms: CD26 antigen, PHARMACOKINETICS, DIABETES, HYPOGLYCEMIC agents

Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects.

Authors: Rajesh RK Krishna, Arthur AB Bergman, Patrick PL Larson, Josee JC Cote, Kenneth KL Lasseter, Stacey SD Dilzer, Amy AW Wang, Wei WZ Zeng, Li LC Chen, John JW Wagner, Gary GH Herman

Source: Journal of Clinical Pharmacology; Feb2007, Vol. 47 Issue 2, p165-174, 10p

Subject Terms: CYCLOSPORINE, CD26 antigen, DIABETES, YOUNG men